The Proteomics Shared Resource provides modern tools of mass spectrometry to Knight Cancer Institute members so that they may determine the identity, abundance, and modifications occurring in proteins, the building blocks of the cell. These analyses are crucial to understanding the cause of cancer and devising improved treatments for the disease, since changes in proteins occur in all forms of cancer. Support will be used to partially fund salaries of five staff and four state-of-the-art mass spectrometers to assist Knight investigators studying cancer-causing changes in proteins, including phosphorylation, acetylation, changes in abundance and altered binding to other proteins. A wide array of informatics tools and expertise will also be provided to Knight members to increase their research productivity. The results from the Proteomics Shared Resource will be used to better treat cancer patients by providing earlier diagnosis of the disease and discovering more effective treatments that are personalized for individual patients.
Alterations in proteins occur in all forms of cancer, and the study of proteins is crucial to devising new treatments and allowing early detection of the disease. The requested support will provide state-of-the-art mass spectrometry and proteomics technologies to Knight Cancer Institute members at The Oregon Health &Science University to speed progress in cancer research.
|Krey, Jocelyn F; Scheffer, Deborah I; Choi, Dongseok et al. (2018) Mass spectrometry quantitation of proteins from small pools of developing auditory and vestibular cells. Sci Data 5:180128|
|Rozanov, Dmitri V; Rozanov, Nikita D; Chiotti, Kami E et al. (2018) MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection. J Proteomics 176:13-23|
|Winters-Stone, Kerri M; Wood, Lisa J; Stoyles, Sydnee et al. (2018) The Effects of Resistance Exercise on Biomarkers of Breast Cancer Prognosis: A Pooled Analysis of Three Randomized Trials. Cancer Epidemiol Biomarkers Prev 27:146-153|
|Pennock, Nathan D; Martinson, Holly A; Guo, Qiuchen et al. (2018) Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. J Immunother Cancer 6:98|
|Xu, Li; Gordon, Ryan; Farmer, Rebecca et al. (2018) Precision therapeutic targeting of human cancer cell motility. Nat Commun 9:2454|
|Chen, Emerson Y; Blanke, Charles D; Haller, Daniel G et al. (2018) A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer. Am J Clin Oncol 41:1193-1198|
|Lane, Ryan S; Femel, Julia; Breazeale, Alec P et al. (2018) IFN?-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin. J Exp Med 215:3057-3074|
|Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96|
|Langer, E M; Kendsersky, N D; Daniel, C J et al. (2018) ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells. Oncogene 37:1005-1019|
|Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019|
Showing the most recent 10 out of 277 publications